Clinical characteristics, prognostic factors, and survival of 393 patients with mycosis fungoides and Sézary syndrome in the southeastern United States: A single-institution cohort - 13/01/15
Abstract |
Background |
Limited data exist on patients with mycosis fungoides (MF) and Sézary syndrome (SS) from the southeastern United States, a region with a high proportion of African Americans (AA).
Objectives |
We sought to determine clinical characteristics, prognostic factors, and survival of patients with MF/SS in a southeastern US cohort, compare with other cohorts, and validate proposed revisions in MF/SS staging.
Methods |
This was a retrospective chart review of patients from an academic dermatology referral center (Atlanta, GA) from 1998 to 2013. Kaplan-Meier estimates were calculated for overall survival, disease-specific survival, and progression; univariate and multivariate Cox proportional hazard models were used for assessment of prognostic variables.
Results |
Of 393 patients, 55.2% were white, 43.3% AA, and 1.5% other; 52.7% were male and 47.3% female (ratio 1.1:1). Mean age was 53.6 years; mean age among AA was 48.9 years. In all, 19.6% died of disease; 21.9% experienced disease progression. Advanced TNMB classification, presence of a circulating clone without phenotypic evidence of blood involvement, and older age were predictors of poor disease-specific survival in the multivariate analysis, whereas AA race was not.
Limitations |
This study was from a single academic center.
Conclusions |
Outcomes of our patients generally paralleled those of other geographic regions. MF/SS may affect younger patients and more women than previously recognized, particularly among AA. Survival among AA may be more favorable than that observed in prior reports. Our data support the validity of the staging criteria revisions for MF/SS.
Le texte complet de cet article est disponible en PDF.Key words : African American, cutaneous T-cell lymphoma, mycosis fungoides, prognosis, survival
Abbreviations used : AA, CTCL, DSS, EORTC, ISCL, MF, OS, PFS, SS
Plan
| Funding sources: None. |
|
| Conflicts of interest: Dr Parker was a principal investigator on a Valeant Pharmaceuticals–sponsored multicenter, randomized, open-label, phase-IV study to assess the efficacy, tolerability, and safety of 2 initial dose levels of bexarotene capsules in patients with refractory cutaneous T-cell lymphoma; no direct financial support was received and this was unrelated to the current report. Dr Desai and Ms Liu have no conflicts of interest to declare. |
|
| Reprints not available from the authors. |
Vol 72 - N° 2
P. 276-285 - février 2015 Retour au numéro
Article précédent
- Effect of tonsillectomy on psoriasis: A systematic review
- Tara D. Rachakonda, Jaskaran S. Dhillon, Aleksandra G. Florek, April W. Armstrong
- Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: Results of a pooled analysis from 3 phase-II clinical trials
- Richard T. Hoppe, Cameron Harrison, Mahkam Tavallaee, Sameer Bashey, Uma Sundram, Shufeng Li, Lynn Million, Bouthaina Dabaja, Pamela Gangar, Madeleine Duvic, Youn H. Kim
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?